Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the ...

Medication stops the attack, but physical therapy rebuilds the strength. Learn how specialized neuro-PT helps ‘re-map’ ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

The FDA on March 16 approved CSL Behring’s drug Hizentra to treat chronic inflammatory demyelinating polyneuropathy. Hizentra is the first subcutaneous immunoglobulin approved to treat CIDP, a rare ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

In addition to working with your neurologist to establish a treatment plan, you can implement a few strategies into your daily or weekly routine to make every day life with CIDP a bit easier. Here are ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

(RTTNews) - argenx SE (ARGX) said that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application or sBLA for VYVGART Hytrulo (efgartigimod ...

Argenx SE (NASDAQ:ARGX) ranks among the best high growth European stocks to buy. On January 12, William Blair maintained its Outperform rating on Argenx SE (NASDAQ:ARGX), citing robust sales growth in ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...